Latest news

• AbbVie takes PARP inhibitor into third phase III trial

  AbbVie now has now closed the gap in the race to bring the first PARP inhibitor to market, particularly with the demise of Sanofi's former leader iniparib last year.

• AZ needs more data on olaparib, says FDA panel

  Moreover, the late-stage failure last year of another PARP inhibitor - Sanofi's iniparib - because of a lack of efficacy may have encouraged caution on the behalf of the panellists.

• Servier expands breast cancer partnership

  Some companies have struggled in the area, however, including Sanofi, which saw its investigational drug iniparib fail to meet trial targets in 2011.

• AZ moves closer to EU approval for ovarian cancer drug

  PARP inhibitors are designed to treat cancer by blocking the repair of DNA in tumour cells, although some of the early drug candidates - notably Sanofi's iniparib - ran into hurdles and

• AZ's olaparib enters phase III for ovarian cancer

  The recent demise of Sanofi's rival candidate iniparib after a phase III trial failure means that AZ is among the leaders in the PARP inhibitor field, although several other drugs